“ipsen” Archives

in
Entry Author Date Location
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More 05/29/20 National
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More 12/20/19 National
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal 12/06/19 National
Tiburio Launches from Cydan with $31M to Tackle Pituitary Tumors 01/03/19 Boston
Rhythm Raises $41M to Bankroll Late-Stage Push For Obesity Drug 02/16/17 Boston
Merrimack Hits Reset Button, Sells Cancer Drugs to Ipsen For $575M 01/08/17 Boston
Allergan Snags Rhythm’s Diabetes-Related GI Drug for $200M 10/27/16 Boston
West Coast Bio Roundup: UCLA Cashes In, BioMarin Tries Again & More 03/04/16 San Francisco
On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug 02/29/16 San Francisco
Actavis Nabs Option to Buy Rhythm Pharma’s GI Drug For Diabetics 10/22/14 Boston
East Coast Biotech Roundup: Biogen, Civitas, Rhythm, Alkermes, & More 08/29/14 Boston
Radius Health Recharges IPO After Two Week Hiatus 05/21/14 Boston
Rhythm Eyes Pivotal Study as GI Drug for Diabetics Hits Phase 2 Mark 05/06/14 Boston
Radius Health Churns Through 3 CEOs, as Osteoporosis Drug Delayed 12/20/13 Boston
East Coast Life Sciences Roundup: Foundation, Ophthotech, Sato, & More 09/27/13 Boston
East Coast Life Sciences Roundup: Alkermes, Ensemble, Sinai, & More 07/19/13 Boston
Pfizer Invests in Rhythm to Support Diabetes, Obesity Drug Programs 11/27/12 Boston
Seventh Sense, Polaris, & More Boston Life Sciences Newsmakers 06/15/12 Boston
Rhythm Drums Up $25M to Advance Diabetes and Obesity Drugs 06/13/12 Boston
Clarus Ventures Adjusts to Unpredictable Biotech World 01/20/12 Boston
Rhythm Adds Former Merck VP as CEO 11/09/11 Boston
Pfizer Axes Celldex Agreement, Vertex’s Telaprevir Performs in Clinical Trial, Anchor Therapeutics Inks Potential $480M Deal With J&J, & More Boston-Area Life Sciences News 09/10/10 Boston
Dicerna Pharma Gets $25M Boost to Develop Next-Gen Gene Silencing Drugs 08/11/10 Boston
$10M for Akorri, $52M for Dyax, A New Partner for Dicerna, & More Boston-Area Deals News 03/31/10 Boston
Dicerna Inks Deal With Ipsen, Second RNAi Partnership of 2010 03/30/10 Boston
Genetix Gets $35M for Gene Therapy, FDA Delays Decision on Alkermes/Amylin Drug, MedMinder and Vitality Tackle Medication Compliance, & More Boston-Area Life Sciences News 03/19/10 Boston
Rhythm Pharma Gets $21M A Round to Target Obesity, Diabetes 03/15/10 Boston
Page 1 of 1